Growth Metrics

Takeda Pharmaceutical (TAK) Non-Current Debt (2018 - 2025)

Historic Non-Current Debt for Takeda Pharmaceutical (TAK) over the last 8 years, with Q4 2025 value amounting to $27.7 billion.

  • Takeda Pharmaceutical's Non-Current Debt fell 1035.26% to $27.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $27.7 billion, marking a year-over-year decrease of 1035.26%. This contributed to the annual value of $26.0 billion for FY2025, which is 1611.52% down from last year.
  • As of Q4 2025, Takeda Pharmaceutical's Non-Current Debt stood at $27.7 billion, which was down 1035.26% from $29.5 billion recorded in Q3 2025.
  • In the past 5 years, Takeda Pharmaceutical's Non-Current Debt ranged from a high of $43.6 billion in Q1 2021 and a low of $26.0 billion during Q1 2025
  • For the 5-year period, Takeda Pharmaceutical's Non-Current Debt averaged around $32.1 billion, with its median value being $30.5 billion (2023).
  • As far as peak fluctuations go, Takeda Pharmaceutical's Non-Current Debt tumbled by 2556.75% in 2022, and later skyrocketed by 653.13% in 2024.
  • Over the past 5 years, Takeda Pharmaceutical's Non-Current Debt (Quarter) stood at $37.2 billion in 2021, then fell by 25.57% to $27.7 billion in 2022, then increased by 4.83% to $29.0 billion in 2023, then grew by 6.53% to $30.9 billion in 2024, then dropped by 10.35% to $27.7 billion in 2025.
  • Its Non-Current Debt was $27.7 billion in Q4 2025, compared to $29.5 billion in Q3 2025 and $28.6 billion in Q2 2025.